Brodeur Melica Nourmoussavi, Dopeso Higinio, Zhu Yingjie, Longhini Ana Leda F, Gazzo Andrea, Sun Siyu, Koche Richard, Qu Rui, Hamard Pierre-Jacques, Bykov Yonina, Green Hunter, Chiappinelli Katherine B, Ozsoy Melih Arda, Basili Thais, Gardner Rui, Walderich Sven, DeStanchina Elisa, Greenbaum Benjamin, Gönen Mithat, Weigelt Britta, Zamarin Dmitriy
bioRxiv. 2023 Aug 11:2023.08.08.552544. doi: 10.1101/2023.08.08.552544.
Cell-intrinsic mechanisms of immunogenicity in ovarian cancer (OC) are not well understood. The presence of damaging mutations in the SWI/SNF chromatin remodeling complex, such as the (BRG1) catalytic subunit, has been associated with improved response to ICB, however the mechanism by which this occurs is unclear. The aim of this current study was to examine the alterations in tumor cell-intrinsic and extrinsic immune signaling caused by loss. Using OC models with loss-of-function mutations in , we found that loss resulted in increased cancer cell-intrinsic immunogenicity, characterized by upregulation of long-terminal RNA repeats such as endogenous retroviruses, increased expression of interferon-stimulated genes, and upregulation of antigen presentation machinery. Notably, this response was dependent on IRF3 signaling, but was independent of the type I interferon receptor. Mice inoculated with cancer cells bearing loss demonstrated increased activation of cytotoxic T cells and NK cells in the tumor microenvironment as well as increased infiltration with activated dendritic cells. These results were recapitulated when animals bearing proficient tumors were treated with a BRG1 inhibitor, suggesting that modulation of chromatin remodeling through targeting may serve as a strategy to reverse immune evasion in OC.
卵巢癌(OC)中免疫原性的细胞内在机制尚未完全了解。SWI/SNF染色质重塑复合物中存在破坏性突变,如(BRG1)催化亚基,与免疫检查点阻断(ICB)反应的改善有关,然而其发生机制尚不清楚。本研究的目的是研究BRG1缺失引起的肿瘤细胞内在和外在免疫信号的改变。使用BRG1功能缺失突变的OC模型,我们发现BRG1缺失导致癌细胞内在免疫原性增加,其特征是内源性逆转录病毒等长末端RNA重复序列上调、干扰素刺激基因的表达增加以及抗原呈递机制上调。值得注意的是,这种反应依赖于IRF3信号传导,但不依赖于I型干扰素受体。接种BRG1缺失癌细胞的小鼠在肿瘤微环境中显示出细胞毒性T细胞和NK细胞的激活增加,以及活化树突状细胞的浸润增加。当用BRG1抑制剂处理携带BRG1功能正常肿瘤的动物时,这些结果得到了重现,这表明通过靶向BRG1调节染色质重塑可能是逆转OC免疫逃逸的一种策略。